Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules

Clara Cesana; Anna Maria Nosari; Catherine Klersy; Sara Miqueleiz; Valentina Rossi; Paola Ferrando; Marina Valentini; Luciana Barbarano; Enrica Morra

Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules

Clara Cesana, Anna Maria Nosari, Catherine Klersy, Sara Miqueleiz, Valentina Rossi, Paola Ferrando, Marina Valentini, Luciana Barbarano, Enrica Morra

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Background and Objectives. We evaluated bacterial infections (Bis) in patients with multiple myeloma (MM) treated with two different schedules of vincristine-adriamycin-dexamethasone (VAD). Design and Methods. Ninety-seven patients were studied during 340 VAD cycles. VAD was given by either continuous intravenous infusion (CII) to hospitalized patients or rapid intravenous infusion (RII) to outpatients. The characteristics of patients and VAD schedules were retrospectively analyzed to detect correlations with the incidence of BI. Results. By analyzing each VAD cycle, we found that profound hypogammaglobulinemia (p=0.06) and posttreatment neutropenia (p=0.08) were associated with a trend for a higher risk of infection, while renal function impairment was significantly correlated with BI risk at both univariate (p

Original language	English
Pages (from-to)	1022-1028
Number of pages	7
Journal	Haematologica
Volume	88
Issue number	9
Publication status	Published - Sep 1 2003

Keywords

Bacterial infection
Multiple myeloma
VAD

ASJC Scopus subject areas

Hematology

Cite this

@article{7d9c5e57806b46d38f9005d2ebd55aa8,

title = "Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules",

abstract = "Background and Objectives. We evaluated bacterial infections (Bis) in patients with multiple myeloma (MM) treated with two different schedules of vincristine-adriamycin-dexamethasone (VAD). Design and Methods. Ninety-seven patients were studied during 340 VAD cycles. VAD was given by either continuous intravenous infusion (CII) to hospitalized patients or rapid intravenous infusion (RII) to outpatients. The characteristics of patients and VAD schedules were retrospectively analyzed to detect correlations with the incidence of BI. Results. By analyzing each VAD cycle, we found that profound hypogammaglobulinemia (p=0.06) and posttreatment neutropenia (p=0.08) were associated with a trend for a higher risk of infection, while renal function impairment was significantly correlated with BI risk at both univariate (p",

keywords = "Bacterial infection, Multiple myeloma, VAD",

author = "Clara Cesana and Nosari, {Anna Maria} and Catherine Klersy and Sara Miqueleiz and Valentina Rossi and Paola Ferrando and Marina Valentini and Luciana Barbarano and Enrica Morra",

year = "2003",

month = sep,

day = "1",

language = "English",

volume = "88",

pages = "1022--1028",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "9",

}

TY - JOUR

T1 - Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules

AU - Cesana, Clara

AU - Nosari, Anna Maria

AU - Klersy, Catherine

AU - Miqueleiz, Sara

AU - Rossi, Valentina

AU - Ferrando, Paola

AU - Valentini, Marina

AU - Barbarano, Luciana

AU - Morra, Enrica

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Background and Objectives. We evaluated bacterial infections (Bis) in patients with multiple myeloma (MM) treated with two different schedules of vincristine-adriamycin-dexamethasone (VAD). Design and Methods. Ninety-seven patients were studied during 340 VAD cycles. VAD was given by either continuous intravenous infusion (CII) to hospitalized patients or rapid intravenous infusion (RII) to outpatients. The characteristics of patients and VAD schedules were retrospectively analyzed to detect correlations with the incidence of BI. Results. By analyzing each VAD cycle, we found that profound hypogammaglobulinemia (p=0.06) and posttreatment neutropenia (p=0.08) were associated with a trend for a higher risk of infection, while renal function impairment was significantly correlated with BI risk at both univariate (p

AB - Background and Objectives. We evaluated bacterial infections (Bis) in patients with multiple myeloma (MM) treated with two different schedules of vincristine-adriamycin-dexamethasone (VAD). Design and Methods. Ninety-seven patients were studied during 340 VAD cycles. VAD was given by either continuous intravenous infusion (CII) to hospitalized patients or rapid intravenous infusion (RII) to outpatients. The characteristics of patients and VAD schedules were retrospectively analyzed to detect correlations with the incidence of BI. Results. By analyzing each VAD cycle, we found that profound hypogammaglobulinemia (p=0.06) and posttreatment neutropenia (p=0.08) were associated with a trend for a higher risk of infection, while renal function impairment was significantly correlated with BI risk at both univariate (p

KW - Bacterial infection

KW - Multiple myeloma

KW - VAD

UR - http://www.scopus.com/inward/record.url?scp=0141702160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141702160&partnerID=8YFLogxK

M3 - Article

C2 - 12969810

AN - SCOPUS:0141702160

VL - 88

SP - 1022

EP - 1028

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -

Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this